Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I SAD study of LPM3770164 in healthy subjects
NCT05238701Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Feb 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LPM3770164 in Huntington disease (HD) and tardive dyskinesia (TD) (2 arms), sponsored by Luye Pharma Group. Primary endpoint: Treatment-emergent adverse effects at Day 28. Started Feb 2022; status: completed.
02
Drugs
LPM3770164
03
Conditions
Huntington disease (HD)tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT05238701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05238701.